ZAFER PEKKOLAY, MAZHAR MÜSLÜM TUNA, Mehmet GÜVEN, ŞADİYE ALTUN TUZCU, İBRAHİM KAPLAN, ZEKİ AKKUŞ, ALPASLAN KEMAL TUZCU

Alternative methods for the diagnosis of macroprolactinemia: urine prolactin level and serum / urine prolactin ratio

Objective: The aim of this study was to investigate the urine prolactin and serum/urine prolactin ratio for accuracydiagnosis of macroprolactinemia.Methods: In the retrospective cross-sectional analysis, prolactin levels (high or normal) in the reproductive period ofmen and women were included in the study. Polyethylene glycol (PEG) precipitation method was used for thedetection of macroprolactinemia. Then, patients were divided into three groups as macroprolactinemia, prolactinomaand healthy control group. In patients, prolactin values in spot urine with simultaneous serum prolactin values werecalculated. The non-parametric Kruskal-Wallis test was used to compare the groups. The receiver-operatingcharacteristic (ROC) curve was determined to evaluate the predictive power of serum/urine prolactin ratio.DOI: 10.5798/dicletip.534848Yazışma Adresi / Correspondence Zafer Pekkolay, Dicle University Faculty of Medicine ,Department of Internal Medicine-Endocrinology, Sur,Diyarbakir, Turkey e-mail: drpekkolay@gmail.comResults: A total of 41 patients were included in the study. Female/male:36 (87.8%)/ 5 (12.2%). Urinary prolactinmedian(minimum-maximum) values were macroprolactinemia, prolactinoma and control group, respectively;0.06(0.05-0.10), 0.11(0.02-0.95), 0.08(0.05-0.25) ng/ml. Serum/urine ratio median (minium-maximum) values weremacroprolactinemia, prolactinoma, and control group, respectively; 633(51-1032), 990(104-9635), 395.5(138-953).When the groups were compared, the patients with prolactinoma had higher urinary prolactin levels(p

Makroprolaktinemi tanısı için alternatif yöntemler: İdrar prolaktin düzeyi ve serum / idrar prolaktin oranı

Amaç: Bu çalışmanın amacı makroprolaktinemi tanısında idrar prolaktin ve serum / idrar prolaktin oranının doğruluğunu araştırmaktır. Yöntemler: Kesitsel analiz olan çalışmamızda, reprodüktif dönemdeki kadın ve erkeklerden prolaktin düzeyi bakılan (yüksek veya normal) hastalar çalışmaya alındı. Makroprolaktinemi tespiti için polietilen glikol (PEG) ile çöktürme yöntemi kullanıldı. Daha sonra hastalar makroprolaktinemi, prolaktinoma ve sağlıklı kontrol grubu olmak üzere üç gruba ayrıldı. Hastalarda eş zamanlı serum prolaktin ve spot idrarda prolaktin çalışıldı. Non-parametrik test olan Kruskal-Wallis testi grupların karşılaştırılmasında kullanıldı. Serum/idrar prolaktin oranının prediktif gücünü değerlendirmek için “receiver-operating characteristic (ROC)” eğrisi belirlendi ve bu analizde “cut-off” değeri elde edildi. Sonuçlar: Çalışmaya toplam 41 hasta dahil edildi. Kadın/erkek: 36 (%87,8) / 5 (%12,2). İdrar prolaktin medyan (minimum-maksimum) değerleri makroprolaktinemi, prolaktinoma ve kontrol grubunda sırasıyla; 0.06(0.05-0.10), 0.11(0.02-0.95), 0.08(0.05-0.25) ng/ml idi. Serum/idrar prolaktin oranı medyan (minimum-maksimum) değerleri makroprolaktinemi, prolaktinoma ve kontrol grubunda sırasıyla; 633(51-1032), 990(104-9635), 395.5(138-953) idi. Gruplar karşılaştırıldığında prolaktinoma olan hastalar daha yüksek üriner prolaktin seviyelerine sahipti. Makroprolaktinemili hastalar en düşük idrar prolaktin değerlerine sahipti(p

PDF

___

Horseman ND and Gregerson KA. Prolactin actions. Journal of Molecular Endocrinology. 2014; 52: 95-106.

Melmed S, Casanueva FF, Hoffman AR, et all. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96: 273-88.

Freeman ME, Kanyicska B, Lerant A, et all. Prolactin: structure, function, and regulation of secretion. Physiological Reviews. 2000; 80: 1523–631.

Molitch ME. Prolactin in human reproduction In: Strauss JF, Barbieri R, eds. Yen and Jaffe's reproductive endocrinology: physiology, pathophysiology, and clinical management, 7th edn. Elsevier Saunders, Philadelphia 2014: 45-65.

Hattori N, Ishihara T, Saiki Y, et all. Macroprolactinaemia in patients with hyperprolactinaemia: composition of macroprolactin and stability during long-term follow-up. Clin Endocrinol (Oxf). 2010; 73: 792–7.

Hattori N, Nakayama Y, Kitagawa K, et all. Antiprolactin (PRL) autoantibody-binding sites (epitopes) on PRL molecule in macroprolactinemia. Clin Endocrinol (Oxf). 2006; 190: 287-93.

Freeman ME, Kanyicska B, Lerant A, et all. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80:1523–631.

Samson SL, Hamrahian AH, Ezzat S. American Association of Clinical Endocrinologists. American College of Endocrinology disease state clinical review: clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia. Endocr Pract. 2015; 21: 1427–35.

Hattori N, Ishihara T, Saiki Y, et all. Macroprolactinaemia in patients with hyperprolactinaemia: composition of macroprolactin and stability during long-term follow-up. Clinical Endocrinology. 2010; 73: 792–7.

Jamaluddin FA, Sthaneshwar P, Hussein Z, et all. Importance of screening for macroprolactin in all hyperprolactinaemic sera. Malays J Patho. 2013; 35: 59–63.

Leslie H, Courtney CH, Bell PM, et all. Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab. 2001; 86: 2743-6.

Silva AM, Costa da PM, Pacheco A, et all. Assessment of macroprolactinemia by polyethylene glycol precipitation method. Revista Portuguesa de Endocrinologia, Diabetes e Metabolismo 2014; 9: 25- 28.

Snyder PJ, Causes of hyperprolactinemia. https://www.uptodate.com/contents/causes of hyperprolactinemia.

Smith TP, Kavanagh L, Healy ML, et all. Technology insight: measuring prolactin in clinical samples. Nature Reviews Endocrinology. 2007; 3: 279-89.

Coppedge RL , Segaloff A. Urinary Prolactin Excretion In Man, The Journal Of Clinical Endocrinology & Metabolism. 1951; 11: 465–76.

Leaños-Miranda A, Márquez-Acosta J, CárdenasMondragón GM, et all. Urinary prolactin as a reliable marker for preeclampsia, its severity, and the occurrence of adverse pregnancy outcomes. J Clin Endocrinol Metab. 2008; 93: 2492-9.

Keely EJ, Charles F. Measurement of human urinary prolactin as a noninvasive study tool. Clinical chemistry. 1994; 40: 2017-21.